Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Robert Sidbury MD, MPH, division head of dermatology at Seattle Children’s Hospital and professor in the department of pediatrics at University of Washington School of Medicine, explored the treatment ...

An OX40 receptor (OX40R ... treatment-experienced, moderate-to-severe atopic dermatitis patient population," said Guttman-Yassky. "Even higher efficacy was observed with rocatinlimab versus ...

In January, Sanofi agreed a $1.45 billion deal to acquire UK biotech Kymab and its lead drug KY1005, an OX40 antibody that like KHK4083 has already cleared a phase 2 trial in atopic dermatitis.

Source Reference: Guttman-Yassky E, et al "Rocatinlimab significantly improved clinical signs and symptoms by targeting OX40+ T cells in patients with moderate-to-severe atopic dermatitis ...

Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...

an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD). The IGNITE study, which evaluated two dose strengths of rocatinlimab ...

So probably the single biggest risk factor for atopic dermatitis is a family history of atopic dermatitis. So if parents, siblings have or have had atopic dermatitis, then that patient's gonna be ...